Parabilis Medicines, Inc. Common Stock (PBLS) — Cash Flow-to-Debt Ratio
Parabilis Medicines, Inc. Common Stock (PBLS) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2026, meaning its operating cash flow of $-3.62 Million could theoretically repay 0% of its total liabilities ($127.53 Million) in one year. See Parabilis Medicines, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Parabilis Medicines, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Parabilis Medicines, Inc. Common Stock across 2 annual periods. See Parabilis Medicines, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Parabilis Medicines, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Parabilis Medicines, Inc. Common Stock. For the full cash flow conversion analysis, see PBLS cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.27x | $-123.71 Million | $97.34 Million | ▼ -13.8% |
| 2024 | -1.12x | $-103.61 Million | $92.81 Million | — |